Anbio Biotechnology Valuation Multiples

Anbio Biotechnology Overview

About Anbio Biotechnology

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

Founded

2021

HQ

Employees

27

Website

anbio.com

Sectors

Medical DevicesHealthTech

Financials (FY)

Revenue: $9M

EBITDA: $6M

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Anbio Biotechnology Financials

Anbio Biotechnology reported last fiscal year revenue of $9M and EBITDA of $6M.

In the same fiscal year, Anbio Biotechnology generated $8M in gross profit, $6M in EBITDA, and $6M in net income.

Anbio Biotechnology P&L

In the most recent fiscal year, Anbio Biotechnology reported revenue of $9M and EBITDA of $6M.

Anbio Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX

Anbio Biotechnology Stock Performance

Anbio Biotechnology has current market cap of $1B, and enterprise value of $1B.

Anbio Biotechnology's stock price is $26.91.

Anbio Biotechnology Valuation Multiples

Anbio Biotechnology trades at 135.2x EV/Revenue multiple, and 202.7x EV/EBITDA.

Anbio Biotechnology Financial Valuation Multiples

As of April 11, 2026, Anbio Biotechnology has market cap of $1B and EV of $1B.

Equity research analysts estimate Anbio Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Anbio Biotechnology has a P/E ratio of 184.4x.

Anbio Biotechnology Margins & Growth Rates

Anbio Biotechnology's revenue in the last fiscal year grew by 6%.

Anbio Biotechnology's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Anbio Biotechnology Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Anbio Biotechnology M&A Activity

Anbio Biotechnology acquired XXX companies to date.

Last acquisition by Anbio Biotechnology was on XXXXXXXX, XXXXX. Anbio Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Anbio Biotechnology Investment Activity

Anbio Biotechnology invested in XXX companies to date.

Anbio Biotechnology made its latest investment on XXXXXXXX, XXXXX. Anbio Biotechnology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).